Eli Lilly Expands Genetic Eye-Disease Focused Pipeline With MeiraGTx Gene Therapy Collaboration MeiraGTx shares rise after signing a $475 million deal with Eli Lilly for a gene therapy program restoring vision in children with LCA4.
There are notable gap-ups and gap-downs in today's session. Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Thursday. Let's explore the market movements and identify the stocks with significant gaps.
MeiraGTx Collaborates With Hologen AI To Expedite Development Of Parkinson's Candidate, Stock Soars MeiraGTx and Hologen form a neuro-AI drug development joint venture, with up to $430M in funding to advance Parkinson's and CNS treatments.
Jim Cramer: This Tech Stock Is A Buy, SoFi Technologies Is Good SoFi Technologies, Inc. is good, Jim Cramer said. It reported third-quarter adjusted sales of $689.445 million, according to Benzinga Pro.
Small Cap-MeiraGTx Reveals Encouraging Data From Parkinson's Study Showing Significant, Clinically Meaningful Changes in Key Efficacy Endpoints MeiraGTx's clinical study of AAV-GAD for Parkinson's disease showed significant improvements in motor function and quality of life in high- and low-dose groups, with no serious adverse events. Participants will be followed for five years in a long-term study.
MGTX Stock Earnings: MeiraGTx Hldgs Misses EPS, Misses Revenue for Q2 2024 MGTX stock results show that MeiraGTx Hldgs missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
Jim Cramer Calls This Healthcare Stock A 'Worthy Spec,' Recommends Avoiding Canada Goose Cramer recommends staying away from Canada Goose, even though it reported better-than-expected Q4 earnings.
MGTX Stock Earnings: MeiraGTx Hldgs Beats EPS, Misses Revenue for Q1 2024 MGTX stock results show that MeiraGTx Hldgs beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
MGTX Stock Earnings: MeiraGTx Hldgs Beats EPS, Misses Revenue for Q4 2023 MGTX stock results show that MeiraGTx Hldgs beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.
Why Is Eye Disease Related Gene Therapy Focused MeiraGTx Stock Soaring Today? MeiraGTx Holdings plc (
NASDAQ: MGTX ) on Thursday announced an asset purchase agreement with Janssen Pharmaceuticals Inc, a Johnson & Johnson (
NYSE: JNJ ) compan
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday It's time to start off Thursday with a breakdown of the biggest pre-market stock movers worth keeping an eye on this morning!
